Mankind Pharma Limited

Mankind Pharma Limited

Mankind Pharma Limited has announced its Q1FY27 financial results, showing revenue growth of 12.9% YoY, EBITDA growth of 24.7% YoY, and PAT growth of 29.1% YoY. The company's domestic business (ex-CH) grew by 11.0% YoY, driven by double-digit growth in Mankind business and strong growth in BSV specialty business. The company has also launched 1 new product in Q1FY27, taking the total launched products to 49 in the US.

Mankind Pharma Limited

Mankind Pharma Limited has announced its Q1 FY27 financial results, showing a 12.9% YoY growth in revenue from operations, with domestic business (ex-CH) growing 11.0% YoY and exports business growing 29.0% YoY. The company has also reported a 16.5% YoY growth in gross profit and a 24.7% YoY growth in EBITDA.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about giving guarantees/indemnity/becoming a surety for a third party, and has also approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the issuance of corporate guarantee in favour of Bharat Serums and Vaccines Limited.

Mankind Pharma Limited

Mankind Pharma Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and has also approved the issuance of a corporate guarantee in favor of Bharat Serums and Vaccines Limited. The company has also provided a certificate from its joint statutory auditors for the quarter ended June 30, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has completed the sale of 100% stake in Broadway Hospitality Services Private Limited for ₹ 49 Crore, as per the Share Purchase Agreement executed on July 27, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about a scheduled investor conference call to discuss Q1FY27 business performance and results on July 30, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about the acquisition of 100% stake in Broadway Hospitality Services Private Limited and the incorporation of a wholly owned subsidiary company in Netherlands to act as a Special Purpose Vehicle for holding investments in R&D assets and business development activities focused on treatment of niche therapies.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming no dematerialisation/rematerialisation of shares for the quarter ended June 30, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about a copy of a newspaper publication regarding the 35th Annual General Meeting (AGM) of the company, scheduled to be held on August 4, 2026, through video conferencing or other audio-visual means.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 04, 2026. The meeting will consider and adopt the Standalone Audited Financial Statements for the Financial Year ended March 31, 2026, and the Report of the Board of Directors and Auditors thereon. The meeting will also consider and if thought fit, pass resolutions for the re-appointment of Mr. Satish Kumar Sharma as Whole Time Director of the Company, and the ratification of the remuneration of Cost Auditors for the Financial Year 2026-27.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange about a newspaper advertisement regarding its 35th Annual General Meeting scheduled to be held on August 4, 2026.

Mankind Pharma Limited

Mankind Pharma Limited has scheduled its 35th Annual General Meeting (AGM) on August 4, 2026, through video conferencing. The notice and annual report for the financial year 2025-26 will be dispatched to members in due course.

Mankind Pharma Limited

Mankind Pharma Limited has informed the Exchange regarding the closure of the trading window for designated persons and their relatives due to the declaration of unaudited financial results for the quarter ending June 30, 2026.